New drug hope for painful hand and foot pustules

NCT ID NCT07000630

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated early with only 3 participants. Researchers aimed to see if the drug could reduce pustules and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Deucravacitinib
What this could lead to
If it works, this could point toward a new oral treatment option for palmoplantar pustulosis, a chronic skin condition with limited therapies.
What could go wrong
The trial was terminated early with only 3 participants, so results are very limited. It is a small, non-randomized study, and the drug may not prove effective or safe in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.